A Phase 1/2 interventional study of placebo and adenosine in Liver Tumors, sponsored by Ludwig-Maximilians - University of Munich. Status unknown. Per ClinicalTrials.gov, last updated 2009-02-18.
Sponsored by Ludwig-Maximilians - University of Munich · Phase 1/2 and Interventional
Liver damage as a consequnce of ischemia (I) and reperfusion (R) is known to harm the liver and could hence be a critical factor of the postoperative outcome of patients undergoing liver surgery. In order to protect the liver from ischemic damage following interventions such as the Pringle Maneuver, preconditioning has been successfully applied in various animal models as well as in humans. Since ischemia inevitably leads to cell hypoxia and subsequnet release of endogenuous metabolites, the investigators hypothesize that instead of brief periods of ischemia, the exogenuous infusion of purine analogues may also protect against subsequent prolonged periods of ischemia. Moreover, after reperfusion, the antiinflamamtory action of purine ananlogue infusion can further attenuated liver damage.
1,390 studies on the registry are indexed under Liver Neoplasms; 345 are open to participants now.
Browse Liver Neoplasms studies →Ludwig-Maximilians - University of Munich is the lead sponsor of 218 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
liver resection with Pringle + placebo
Drug: placebo · Procedure: Liver resection
liver resection with Pringle + adenosine preconditiong
Drug: adenosine · Procedure: Liver resection
liver resection with Pringle + adenosine pre- and postconditioning
Drug: adenosine · Procedure: Liver resection
NaCl 0,9 %
intravenous infusion of adenosine 0, 2 %
intravenous infusion of adenosine 0,2 %
Liver resection with Pringle maneuver
No study locations are listed for this record.
This study is status unknown, as verified in Feb 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ludwig-Maximilians - University of Munich